Menu
Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Volume 2
Insulin glulisine in the management of diabetes
Authors Yamada S
Published 7 July 2009 Volume 2009:2 Pages 111—115
DOI https://doi.org/10.2147/DMSO.S3404
Review by Single anonymous peer review
Peer reviewer comments 2
Satoru Yamada1,2
1Diabetes Center, Kitasato Institute Hospital, Tokyo, Japan; 2Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Abstract: Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still relatively unknown. The frequency of hypoglycemia, convenience in the timing of administration, and improvements in terms of HbA1c seem similar among the rapid-acting insulin analogs, including insulin glulisine. Only properly randomized long-term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog.
Keywords: insulin analog, rapid-acting insulin, trometamol, polysorbate 20
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.